Altimmune, Inc.

Altimmune, Inc. is a late clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, focused on developing novel peptide-based therapeutics for serious liver and metabolic diseases. The company's mission centers on creating innovative and differentiated treatments to address significant unmet medical needs in conditions such as metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).

The company's lead product candidate is pemvidutide, a unique GLP-1/glucagon dual receptor agonist. This therapy is designed to target both glucagon and GLP-1 receptors in a balanced 1:1 ratio, aiming to mimic the complementary effects of diet and exercise by suppressing appetite, increasing energy expenditure, and directly impacting hepatic fat metabolism. Pemvidutide is currently in development for MASH, AUD, ALD, and obesity, representing key market segments for Altimmune.

In recent leadership changes, Jerry Durso assumed the role of President, Chief Executive Officer, and Chairman of the Board effective January 1, 2026. Altimmune has made notable progress with pemvidutide, including receiving FDA Breakthrough Therapy Designation for MASH. The company successfully closed a $225 million public offering in April 2026 to fund the continued development of its lead candidate, with a Phase 3 MASH trial planned for 2026. Topline data from the RECLAIM Phase 2 trial for AUD is anticipated in the third quarter of 2026, and the RESTORE Phase 2 trial for ALD was initiated in the third quarter of 2025. Altimmune is positioned as a high-risk, high-reward biopharmaceutical company, with its near-term trajectory largely dependent on the success of pemvidutide in these significant markets.

Latest updates

Altimmune Secures $225 Million Funding to Advance MASH Trial

Event summary

  • Altimmune closed a $225 million public offering of common stock and warrants.
  • The financing included an additional $225 million warrant tranche.
  • Proceeds will fund operations through the anticipated Phase 3 data readout for pemvidutide, targeting metabolic dysfunction-associated steatohepatitis (MASH).
  • The offering was led by Deep Track Capital and included participation from several other institutional investors.

The big picture

Altimmune's financing underscores the intense investment activity surrounding MASH therapeutics, a market with significant unmet need and potential for blockbuster drugs. The oversubscribed nature of the offering suggests strong investor appetite for companies tackling this disease, but also highlights the inherent risks associated with late-stage clinical development. The warrant structure, while providing upfront capital, introduces complexity and potential dilution that investors will need to monitor.

What we're watching

Clinical Execution
The success of Altimmune hinges on the timely and successful completion of the Phase 3 MASH trial; delays or negative data could significantly impact the stock price.
Investor Sentiment
The participation of high-profile investors like Deep Track Capital and RA Capital suggests confidence, but future performance will be scrutinized closely.
Warrant Dynamics
The structure of the offering, including the warrants with a time-dependent exercise window, creates potential dilution and will be a key factor in shareholder value.
CID: 2919